AKNA Is a Potential Prognostic Biomarker in Gastric Cancer and Function as a Tumor Suppressor by Modulating EMT-Related Pathways

Table 1

The relationship between AKNA expression level and clinicopathological factors in 354 GC cases from the TCGA database.

Characteristics		Expression of AKNA
		Low	High
Gender	354	101	253	0.108	0.742
Male	229	64 (27.9%)	165
Female	125	37 (29.6%)	88
Age(years)	351	101	250	3.41	0.065
≤65	150	37 (24.7%)	113
>65	201	64 (31.8%)	137
Tumor sites	340	96	244	13.256	0.004
Gastroesophageal junction	39	16 (41.0%)	23
Cardiac	45	19 (42.2%)	26
Fundus/body	124	23 (18.5%)	101
Antrum	132	38 (28.8%)	94
WHO’s histological types	103	24	79	3.005	0.391
Tubular Ade.
Moderately Diff.	5	2 (40.0%)	3
Poorly Diff.	68	18 (26.5%)	50
Mucinous Ade.	11	1 (9.1%)	10
Signet ring cell car.	19	3 (15.8%)	16
Lauren’s types^a	233	65	168	1.668	0.196
Intestinal type	161	49 (30.4%)	112
Diffuse type	72	16 (22.2%)	56
Depth of invasion	354	101	253	2.339	0.505
T1	18	7 (38.9%)	11
T2	62	20 (32.3%)	42
T3	12	2 (16.7%)	10
T4	262	72 (27.5%)	190
Ln metastasis	318	83	235	2.375	0.498
N0	89	25 (28.1%)	64
N1	66	19 (28.8%)	47
N2	73	14 (19.2%)	59
N3	90	25 (27.8%)	65
Distant metastasis	338	97	241	9.337	0.002
M0	315	84 (26.7%)	231
M1	23	13 (56.5%)	10
TNM staging	306	82	224	15.012	0.002
I	42	15 (35.7%)	27
II	57	15 (26.3%)	42
III	184	39 (21.2)	145
IV	23	13 (56.5%)	10

Ade.: adenocarcinoma; Diff.: differentiated; Car.: carcinoma; Ln.: lymph node.^aLauren’s types data of 121 GC cases is unavailable.